Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Navios South American Logistics Inc. Announces Submission of Confidential Draft Registration .
Navios South American LogisticsJanuary 20, 2021 GMT
MONTEVIDEO, Uruguay, Jan. 20, 2021 (GLOBE NEWSWIRE) Navios South American Logistics Inc. (“Navios Logistics” or the “Company”) announces it has confidentially submitted a draft Registration Statement on Form F-1 to the United States Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.
Navios South American Logistics Inc. Announces Submission of Confidential Draft Registration Statement
MONTEVIDEO, Uruguay, Jan. 20, 2021 (GLOBE NEWSWIRE) Navios South American Logistics Inc. (“Navios Logistics” or the “Company”) announces it has confidentially submitted a draft Registration Statement on Form F-1 to the United States Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.
Published: Jan 19, 2021
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) Brickell Biotech Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the efficacy and safety results from the pivotal Phase 3 study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology
1.
The paper, entitled “A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis,” is available online in English at the Wiley Online Library (click here).
Home / Top News / Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services’ Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices
Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services’ Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices
NEWTOWN, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today provided comments in response to a press release issued by the Centers for Medicare & Medicaid Services (“CMS”) on Tuesday, January 12, 2021.
In the press release, CMS stated that it is finalizing a new Medicare coverage pathway, Medicare Coverage of Innovative Technology, or “MCIT,” for Food and Drug Administration (“FDA”)-designated breakthrough medical devices. The MCIT rule will provide national